InflaRx (IFRX) Preferred Shares (2016 - 2017)
InflaRx's (IFRX) quarterly Preferred Shares came in at $67.5 million in Q3 2017, up 16.95% quarter-over-quarter from $57.7 million in Q4 2016.
Analysis
InflaRx (IFRX) Preferred Shares (2016 - 2017) Analysis & Trends
InflaRx has disclosed Preferred Shares across 2 years of filings, most recently posting $67.5 million for Q3 2017.
- In Q3 2017, Preferred Shares changed N/A year-over-year to $67.5 million; the TTM figure through Sep 2017 stood at $67.5 million (changed N/A YoY), while the FY2016 annual figure was $59.2 million, changed N/A from the prior year.
- Preferred Shares came in at $67.5 million for Q3 2017 at InflaRx, up from $57.7 million in the prior quarter.
- In the past five years, Preferred Shares ranged from a high of $67.5 million in Q3 2017 to a low of $57.7 million in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | - |